Terbinafine stimulates the pro-inflammatory responses in human monocytic THP-1 cells through an ERK signaling pathway.

AIMS Oral antifungal terbinafine has been reported to cause liver injury with inflammatory responses in a small percentage of patients. However the underlying mechanism remains unknown. To examine the inflammatory reactions, we investigated whether terbinafine and other antifungal drugs increase the release of pro-inflammatory cytokines using human monocytic cells. MAIN METHODS Dose- and time-dependent changes in the mRNA expression levels and the release of interleukin (IL)-8 and tumor necrosis factor (TNF)α from human monocytic THP-1 and HL-60 cells with antifungal drugs were measured. Effects of terbinafine on the phosphorylation of extracellular signal-regulated kinase (ERK)1/2, p38 mitogen-activated protein (MAP) kinase and c-Jun N-terminal kinase (JNK)1/2 were investigated. KEY FINDINGS The release of IL-8 and TNFα from THP-1 and HL-60 cells was significantly increased by treatment with terbinafine but not by fluconazole, suggesting that terbinafine can stimulate monocytes and increase the pro-inflammatory cytokine release. Terbinafine also significantly increased the phosphorylation of ERK1/2 and p38 MAP kinase in THP-1 cells. Pretreatment with a MAP kinase/ERK kinase (MEK)1/2 inhibitor U0126 significantly suppressed the increase of IL-8 and TNFα levels by terbinafine treatment in THP-1 cells, but p38 MAPK inhibitor SB203580 did not. These results suggested that an ERK1/2 pathway plays an important role in the release of IL-8 and TNFα in THP-1 cells treated with terbinafine. SIGNIFICANCE The release of inflammatory mediators by terbinafine might be one of the mechanisms underlying immune-mediated liver injury. This in vitro method may be useful to predict adverse inflammatory reactions that lead to drug-induced liver injury.

[1]  A. DeFranco,et al.  The role of tyrosine kinases and map kinases in LPS-induced signaling. , 1998, Progress in clinical and biological research.

[2]  F. B. Padilla,et al.  Terbinafine hepatotoxicity. A case report and review of literature. , 2003, Annals of hepatology.

[3]  N. Shear,et al.  Terbinafine: an update. , 1997, Journal of the American Academy of Dermatology.

[4]  T. Kurth,et al.  The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. , 2007, The American journal of medicine.

[5]  J. Kovarik,et al.  Dose‐proportional pharmacokinetics of terbinafine and its N‐demethylated metabolite in healthy volunteers , 1992, The British journal of dermatology.

[6]  M. Ingelman-Sundberg,et al.  Pro-inflammatory response and adverse drug reactions: mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[7]  J. Shabanowitz,et al.  Identification of the regulatory phosphorylation sites in pp42/mitogen‐activated protein kinase (MAP kinase). , 1991, The EMBO journal.

[8]  B. Dewald,et al.  Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines. , 1994, Advances in immunology.

[9]  M. Browning,et al.  Phenotypic and functional differentiation of KG-1 into dendritic-like cells. , 2008, Immunobiology.

[10]  J. Luyendyk,et al.  Inflammation and Drug Idiosyncrasy—Is There a Connection? , 2003, Journal of Pharmacology and Experimental Therapeutics.

[11]  P. Krupp,et al.  Safety of oral terbinafine : Results of a postmarketing surveillance study in 25 884 Patients , 1997 .

[12]  S. Geller,et al.  Terbinafine Hepatotoxicity: Case Report and Review of the Literature , 1998, American Journal of Gastroenterology.

[13]  B. Stricker,et al.  A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. , 2001, British journal of clinical pharmacology.

[14]  S. Iverson,et al.  Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. , 2001, Chemical research in toxicology.

[15]  Y. Honma,et al.  Pyridinyl imidazole inhibitor SB203580 activates p44/42 mitogen-activated protein kinase and induces the differentiation of human myeloid leukemia cells. , 2001, Leukemia research.

[16]  M. Cobb,et al.  Pharmacological inhibitors of MAPK pathways. , 2002, Trends in pharmacological sciences.

[17]  B. Stricker,et al.  Terbinafine-associated hepatic injury. , 1994, Journal of hepatology.

[18]  D. Dhumeaux,et al.  Case Report: Terbinafine-Induced Prolonged Cholestasis with Reduction of Interlobular Bile Ducts , 1997, Digestive Diseases and Sciences.

[19]  P. O'Brien,et al.  Oxidative Stress Mediated Idiosyncratic Drug Toxicity , 2005, Drug metabolism reviews.

[20]  N. Shear,et al.  Hypersensitivity reaction to terbinafine. , 1997, Journal of the American Academy of Dermatology.

[21]  J. Uetrecht,et al.  New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. , 1999, Chemical research in toxicology.

[22]  H. Jaeschke.  Role of inflammation in the mechanism of acetaminophen-induced hepatotoxicity , 2005, Expert opinion on drug metabolism & toxicology.

[23]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[24]  M. Raffeld,et al.  Neutrophil recruitment by intradermally injected neutrophil attractant/activation protein-1. , 1991, The Journal of investigative dermatology.

[25]  M. Manns,et al.  I. TNF-induced liver injury. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[26]  J. Luyendyk,et al.  Inflammatory Stress and Idiosyncratic Hepatotoxicity: Hints from Animal Models , 2009, Pharmacological Reviews.

[27]  M. Watabe,et al.  Regulation of ERK-mediated signal transduction by p38 MAP kinase in human monocytic THP-1 cells. , 2003, Journal of biochemistry.

[28]  J. Luyendyk,et al.  Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. , 2004, Chemico-biological interactions.

[29]  M. Ingelman-Sundberg,et al.  Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[30]  Shin-ichiro Takahashi,et al.  The p38 pathway inhibitor SB202190 activates MEK/MAPK to stimulate the growth of leukemia cells. , 2009, Leukemia research.